A standardized behavioral test battery to identify and validate targets for neuropsychiatric diseases and pain

Experimental Animal Models in Neurobehavioral Research

Volumn , Issue , 2008, Pages 17-46

  Pogorelov, Vladimir M ^a   Baker, Kevin B ^a   Malbari, Murtaza M ^a   Lanthorn, Thomas H ^a   Savelieva, Katerina V ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Behavior test battery; Knockout mice; Novel drug targets; Predictive validity

Indexed keywords

EID: 54849410018     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (84)

1. Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP. Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol., 2002; 20:36-42.
2. Allen JW, Yaksh TL. Tissue injury models of persistent nociception in rats. Methods Mol Med., 2004; 99:25-34.
3. American Psychiatric Association, 1994. Diagnostic and statistical manual of mental disorders, 4th edition. American Psychiatric Press, Washington, DC.
4. Anger WK. Animal test systems to study behavioral dysfunctions of neurodegenerative disorders. Neurotoxicology, 1991; 12:403-13.
5. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol., 2002; 68:209-45.
6. Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, Grieder FB, Heintz N, Hicks G, Insel TR, Joyner A, Koller BH, Lloyd KC, Magnuson T, Moore MW, Nagy A, Pollock JD, Roses AD, Sands AT, Seed B, Skarnes WC, Snoddy J, Soriano P, Stewart DJ, Stewart F, Stillman B, Varmus H, Varticovski L, Verma IM, Vogt TF, von Melchner H, Witkowski J, Woychik RP, Wurst W, Yancopoulos GD, Young SG, Zambrowicz B. The knockout mouse project. Nat Genet, 2004; 36:921-4.
7. Bing O, Heilig M, Kakoulidis P, Sundblad C, Wiklund L, Eriksson E. High doses of testosterone increase anticonflict behaviour in rat. Eur Neuropsychopharmacology, 1998; 8:321-323.
8. Bonnefont J, Alloui A, Chapuy E, Clottes E, Eschalier A. Orally administered paracetamol does not act locally in the rat formalin test: evidence for a supraspinal, serotonin-dependent antinociceptive mechanism. Anesthesiology, 2003; 99:976-81.
9. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl)., 2001;156:234-58.
10. Buresova O, Bolthius J, Bures J. Differential effects of cholinergic blockade on performance of rats in the water tank navigation task and in the radial maze. Behav Neurosci, 1986; 100:476-482.
11. Carlton SM, Zhou S. Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. Pain, 1998; 76:201-7.
12. Cesena RM, Calcutt NA. Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. Neurosci Lett 1999; 262:101-104.
13. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science, 1999; 284:1670-1672.
14. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev., 2005a; 29:547-69.
15. Cryan JF, Page ME, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl)., 2005b;182:335-44.
16. Cryan JF, Slattery DA. Animal models of mood disorders: Recent developments. Curr Opin Psychiatry., 2007; 20:1-7.
17. Davis M, Astrachan DI. Conditioned fear and startle magnitude:effects of different footshock or backshock intensities used in training. J Exp Psychol: Animal Behav Proc, 1978; 4: 95-103.
18. Davis M. Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology (Berl)., 1979; 62:1-7.
19. Davis M, Falls WA, Campeau S, Kim M. Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res., 1993; 58:175-98.
20. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev., 2001; 36:60-90.
21. Dixit RK, Bhargava VK. Neurotransmitter mechanisms in gabapentin antinociception. Pharmacology, 2002; 65:198-203.
22. Drugan RC, Skolnick P, Paul SM, Crawley JN. A pretest procedure reliably predicts performance in two animal models of inescapable stress. Pharmacol Biochem Behav., 1989; 33:649-54.
23. Einat H. Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet., 2007; 37:244-55.
24. Falls WA, Carlson S, Turner JG, Willott JF. Fear-potentiated startle in two strains of inbred mice. Behav Neurosci., 1997; 111:855-61.
25. Falls, WA. Fear-potentiated startle in mice. In J. Crawley (Ed.), Current protocols in neuroscience, 2002; Suppl. 19, pp. Unit 8.11-B1-8.11-B16. New York: Wiley.
26. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol., 1997; 121:1513-22.
27. Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA, Marsden CA, Chapman V. Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci., 2004; 19:678-86.
28. Friddle CJ, Abuin A, Ramirez-Solis R, Richter LJ, Buxton EC, Edwards J, Finch RA, Gupta A, Hansen G, Holt KH, Hu Y, Huang W, Jaing C, Key BW, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Newhouse M, Perry T, Platt KA, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Tran D, Wann ER, Walke W, Wallace JD, Xu N, Zhu Q, Person C, Sands AT, Zambrowicz BP. High-throughput mouse knockouts provide a functional analysis of the genome. Cold Spring Harb Symp Quant Biol., 2003; 68:311-5.
29. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl)., 2001; 156:117-54.
30. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry., 2002; 7:1039-53.
31. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry., 2003; 160:636-45.
32. Gould TD, Gottesman II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav., 2006; 5:113-9.
33. Heldt S, Sundin V, Willott JF, Falls WA. Posttraining lesions of the amygdale interefere with fear-potentiated startle to both visual and auditory conditioned stimuli in C57BL/6J mice. Behav Neurosci, 2000; 114: 749-759.
34. Herrera-Morales W, Mar I, Serrano B, Bermúdez-Rattoni F. Activation of hippocampal postsynaptic muscarinic receptors is involved in long-term spatial memory formation. Eur J Neurosci., 2007; 25:1581-8.
35. Holmes A, Wrenn CC, Harris AP, Thayer KE, Crawley JN. Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav., 2002; 1:55-69.
36. Janas AM, Cunningham SC, Duffy KB, Devan BD, Greig NH, Holloway HW, Yu QS, Markowska AL, Ingram DK, Spangler EL. The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. Life Sci., 2005; 76:1073-81.
37. Jia Z, Lu YM, Agopyan N, Roder J. Gene targeting reveals a role for the glutamate receptors mGluR5 and GluR2 in learning and memory. Physiol Behav., 2001; 73:793-802.
38. Jourdan D, Ardid D, Bardin L, Bardin M, Neuzeret D, Lanphouthacoul L, Eschalier A. A new automated method of pain scoring in the formalin test in rats. Pain, 1997; 71:265-70.
39. Kazdoba T, Del Vecchio RA, Hyde LA. Automated evaluation of shock sensitivity in mice: inbred strain differences and pharmacological validation. Behav Pharmacol, 2007; 18: 89-102.
40. Koller BH, Hagemann LJ, Doetschman T, Hagaman JR, Huang S, Williams PJ, First NL, Maeda N, Smithies O. Germ-line transmission of a planned alteration made in a hypoxanthine hosphoribosyltransferase gene by homologous recombination in embryonic stem cells. Proc Natl Acad Sci U S A, 1989; 86:8927-31.
41. Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des., 2004; 10:3111-9.
42. Lamberty Y, Gower AJ. Cholinergic modulation of spatial learning in mice in a Morris-type water maze. Arch Int Pharmacodyn Ther., 1991; 309:5-19.
43. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther., 2002; 302:1168-75.
44. Lemberg K, Kontinen VK, Viljakka K, Kylänlahti I, Yli-Kauhaluoma J, Kalso E. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg., 2006; 102:1768-74.
45. Lipp HP, Wolfer DP. Genetically modified mice and cognition. Curr Opin Neurobiol., 1998; 8:272-80.
46. Malmberg AB, Yaksh TL. Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. Anesthesiology., 1993; 79:270-81.
47. McCaughran JA, Bell J, Hitzemann RJ. Fear-potentiated startle response in mice: genetic analysis of the C57BL/6J and DBA/2J intercross. Pharmacol Biochem Behav., 2000; 65:301-12.
48. McCormack K, Prather P, Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain, 1998; 78:79-98.
49. McNamara RK, Skelton RW. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Brain Res Rev., 1993; 18:33-49.
50. Moran PM, Higgins LS, Cordell B, Moser PC. Age-related learning deficits in transgenic mice expressing the 751-aminoacid isoform of human ß-amyloid precursor protein. Proc Natl Acad Sci, 1995; 92:5341-5345.
51. Morgan CA, Grillon C, Southwick SM, Davis M, Charney DS. Fear-potentiated startle in posttraumatic stress disorder. Biol Psychiatry, 1995; 38: 378-385.
52. Morris RGM, Garrud P, Rawlins JNP, O'Keefe J. Place navigation impaired in rats with hippocampal damage. Nature, 1982; 297:681-683.
53. Morse, H.C. III, editor, Origins of Inbred Mice, NIAID/NIH, Academic Press, New York, 1978.
54. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat., 2003; 26:233-42.
55. Murray CW, Porreca F, Cowan A. Methodological refinements to the mouse paw formalin test. An animal model of tonic pain. J Pharmacol Methods, 1988; 20:175-86.
56. Nishimura H, Tsuda A, Oguchi M, Ida Y, Tanaka M. Is immobility of rats in the forced swim test " behavioral despair" Physiol Behav, 1988; 42:93-95.
57. O'Keefe J, Nadel L. The hippocampus as a cognitive map. 1978, Oxford: Oxford University Press.
58. Pogorelov VM, Lanthorn TH, Savelieva KV. Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice. J. Neurosci. Methods, 2007; 162: 222-228.
59. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature, 1977; 66:730-732.
60. Powell CM, Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry, 2006; 59:1198-207.
61. Randolph BC, Peters MA. Analgesic effectiveness of ketorolac compared to meperidine in the rat formalin test. Anesth Prog., 1997; 44:11-6.
62. Risbrough VB, Brodkin JD, Geyer MA. GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology, 2003; 28:654-63.
63. Risbrough VB, Geyer MA. Anxiogenic treatments do not increase fear-potentiated startle in mice. Biol Psychiatry, 2005; 57:33-43.
64. Rooks WH. The pharmacologic activity of ketorolac tromethamine. Pharmacotherapy, 1990; 10(6 (Pt 2)):30S-32S.
65. Sakata Y, Chida R, Ishige K, Edagawa Y, Tadano T, Ito Y. Effect of a nutritive-tonic drink on scopolamine-induced memory impairment in mice. Biol Pharm Bull., 2005; 28:1886-91.
66. Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, Sharp JJ. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nat Genet., 1997; 16:19-27.
67. Slingsby JH, Hogarth MB, Simpson E, Walport MJ, Morley BJ. New microsatellite polymorphisms identified between C57BL/6, C57BL/10, and C57BL/KsJ inbred mouse strains. Immunogenetics, 1996; 43(1-2):72-5.
68. Sommer W, Moller C, Wiklund L, Thorsell A, Rimondini R, Nissbrandt H, Heilig M. Local 5,7-Dihydroxytryptamine Lesions of Rat Amygdala: Release of Punished Drinking, Unaffected Plus-Maze Behavior and Ethanol Consumption. Neuropsychopharmacology, 2001; 24:430-440.
69. Squire LR. Memory and brain. 1987; New York: Oxford University Press.
70. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology, 1985; 85:367-70.
71. Swerdlow NR, Braff DL, Geyer MA. Cross-species studies of sensorimotor gating of the startle reflex. Ann N Y Acad Sci, 1999; 877:202-16.
72. Thierry B, Steru L, Chermat R, Simon P. Searching-waiting strategy: a candidate for an evolutionary model of depression? Behav Neural Biol, 1984; 41:180-189.
73. Tucker PK, Lee BK, Lundrigan BL, Eicher EM. Geographic origin of the Y chromosomes in " old" inbred strains of mice. Mamm Genome, 1992; 3(5):254-61.
74. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology 1971, 21:1-7.
75. Walke DW, Han C, Shaw J, Wann E, Zambrowicz B, Sands A. In vivo drug target discovery: identifying the best targets from the genome. Curr Opin Biotechnol, 2001; 12: 626-31.
76. Weiss IC, Feldon J. Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review. Psychopharmacology (Berl), 2001; 156:305-26.
77. West DB, Iakougova O, Olsson C, Ross D, Ohmen J, Chatterjee A. Mouse genetics/genomics: an effective approach for drug target discovery and validation. Med Res Rev., 2000; 20:216-30.
78. Wheeler-Aceto H, Cowan A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology (Berl), 1991; 104:35-44.
79. Willner P. The validity of the animal models of depression. Psychopharmacology, 1984, 83:1-16.
80. Yaksh TL, Ozaki G, McCumber D, Rathbun M, Svensson C, Malkmus S, Yaksh MC. An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol., 2001; 90:2386-402.
81. Yoon MH, Choi JI, Kim SJ, Kim CM, Bae HB, Chung ST. Synergistic antinociception between zaprinast and morphine in the spinal cord of rats on the formalin test. Eur J Anaesthesiol., 2006; 23:65-70.
82. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol., 2003a; 3:563-70.
83. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW, Jr., Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C and Sands AT. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci U S A, 2003b; 100:14109-14114.
84. Zheng B, Sage M, Cai WW, Thompson DM, Tavsanli BC, Cheah YC and Bradley A. Engineering a mouse balancer chromosome. Nat Genet, 1999; 22:375-378.